# US 12,594,331 B2 · Methods of treating psoriasis with secukinumab

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,331 B2
- Document ID: US12594331B2
- Status: Granted
- Kind: B2
- Application number: 18/983,034
- Filed: 2024-12-16
- Published: 2025-05-22
- Granted: 2026-04-07
- Earliest claimed: 2010-10-08
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Achim Guettner; Matthias Machacek; Charis Papavassilis; Oliver Sander
- Web page: https://patentgrep.com/patent/US12594331B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 17/06: Antipsoriatics
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.

## Claims

### Claim 1

A method of treating psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has plaque psoriasis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient has moderate to severe plaque psoriasis.

### Claim 4 (depends on 3)

The method of claim 3, wherein the patient is a candidate for systemic therapy or phototherapy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient weighs less than 70 kg.

### Claim 6

A method of treating moderate to severe plaque psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection at each of weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter, wherein the patient weighs less than 70 kg.

### Claim 7

A method of treating psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection weekly for 4 or 5 weeks, and every 4 weeks thereafter.

### Claim 8 (depends on 7)

The method of claim 7, wherein the patient has plaque psoriasis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the patient has moderate to severe plaque psoriasis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the patient is a candidate for systemic therapy or phototherapy.

### Claim 11 (depends on 7)

The method of claim 7, wherein the patient weighs less than 70 kg.

### Claim 12 (depends on 7)

The method of claim 7, wherein the patient had plaque psoriasis at the time of the first weekly subcutaneous injection.

### Claim 13 (depends on 12)

The method of claim 12, wherein the patient had moderate to severe plaque psoriasis at the time of the first weekly subcutaneous injection.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient was a candidate for systemic therapy or phototherapy at the time of the first weekly subcutaneous injection.

### Claim 15 (depends on 12)

The method of claim 12, wherein the patient weighs less than 70 kg.

### Claim 16

A method of treating moderate to severe plaque psoriasis, comprising administering to a patient in need thereof about 75 mg secukinumab by subcutaneous injection weekly for 4 or 5 weeks, and every 4 weeks thereafter; wherein the patient weights less than 70 kg, and is a candidate for systemic therapy or phototherapy.